

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

POSITIVE PROFIT ALERT

This announcement is made by Tongfang Kontafarma Holdings Limited (the “**Company**”) and, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the latest unaudited consolidated management accounts of the Group for the year ended 31 December 2018 (the “**FY 2018**”), the Group is expected to record an increase of not less than 30% in the net profit as compared to the year ended 31 December 2017. The Board considers that such increase in the net profit was primarily attributable to the increase in revenue recorded by the Group as a result of its better business performance in the FY 2018 and the effectiveness of the costs control measures adopted by the Group in its business operation.

The information in this announcement is based on a preliminary assessment by the management of the Company with reference to the unaudited consolidated management accounts of the Group for the FY 2018. Such information has not been finalised, audited or reviewed by the Company’s independent auditor, and has not been confirmed by the audit committee of the Board. The finalised audited consolidated results of the Group for the FY 2018 are expected to be announced by the end of March 2019, which may differ from the figures and information provided in this announcement.

Shareholders and potential investors are advised to exercise caution when dealing in the shares or other securities of the Company.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 6 March 2019

As at the date of this announcement, the Board comprises two executive directors, namely Mr. Huang Yu (Chairman) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.